一、基本情况
肖政，男，1974.3，贵州省遵义县人，2010年毕业于四川大学，获医学博士，临床医学（移植科学与工程学）专业，教授（2018年）,全科医学及公共管理学硕士导师。遵义医科大学循证医学中心（循证医学教育部网上合作研究中心遵义医学院分中心），循证医学办公室副主任。
二、主要学术兼职
中国医疗保健国际交流促进会循证医学分会常务委员/学术委员；中华医学会临床流行病学与循证医学分会青年委员；中国医师协会循证医学专业委员会学术委员；中华预防医学会循证预防医学专业委员会学术委员；贵州省医学会临床流行病学分会常务委员。《医学新知杂志》和《实用心脑肺血管病杂志》、编委，《Phytomedicine》，《International Immunopharmacology》及《Clinical Therapeutics》等杂志审稿专家。
三、荣誉称号
贵州省2015年度高层次创新型人才（千层次）.
四、主要研究方向
循证管理与决策，循证药学及循证全科实践与创新研究。
五、承担及参与项目
主持/参与省级项目及计划7项
1.贵州省中医药管理局中医药、民族医药科学技术研究课题，QzYY2017-084， 斑蝥及其衍生药物辅助抗癌体系的临床真实疗效及安全性循证再评价研究，主持（结题）
2. 贵州省市院联合基金项目，黔科合LH字[2016]7485号，肺癌免疫治疗体系的真实疗效、安全性及机制证据链研究，主持（结题）.
3.贵州省哲学社会科学规划项目，14GZYB58，基于疾病谱的贫困地区乡镇卫生院医疗 服务能力提升策略研究，主持（结题）
4.贵州省教育厅创新群体重大研究项目，cj-931， 多学科协作肾移植能力提升策略研究，2018/01-2020/12，20万元，参与(结题)
5.贵州省2015年度高层次创新型人才（千层次）计划项目（结题）
6.遵义医学院2017年度学术新苗培养及创新探索专项（结题）
7.西部地区城市中心医院功能的区域延伸及运作机制研究：以遵义为例，遵义医学院博士启动基金，结题
六、发表论文
参加工作以来，累计发表论文126篇，SCI论文27篇，近五年发表论文29篇，SCI论文21篇，5分以上论文10篇。
近五年发表相关论文如下：
[1] Wang CQ, Xu J, Jiang H, et al. The evidence framework of traditional Chinese medicine injection (Aidi injection) in controlling malignant pleural effusion: A clustered systematic review and meta-analysis. Phytomedicine, 2023, 115: 154847.
[2] Wang CQ, Shen YS, Chen XF, et al. The intrapleural administration with thymic peptides in malignant pleural effusion: A clustered systematicreview and meta-analysis. Int Immunopharmacol, 2022, 107: 108688.
[3] Jiang H, Yang XM, Wang CQ, et al. Intrapleural Perfusion With Staphylococcal Enterotoxin C for Malignant Pleural Effusion: A Clustered Systematic Review and Meta-Analysis. Front Med (Lausanne), 2022, 9: 816973.
[4] Chen Q, Xiao Z, He QY, et al. Effect of Shenling Baizhu powder on immunity to diarrheal disease: A systematic review and meta-analysis. Front Pharmacol, 2022, 13: 938932.
[5] Wang CQ, Zheng XT, Chen XF, et al. The Optimal Adjuvant Strategy of Aidi Injection With Gemcitabine and Cisplatin in Advanced Non-small Cell Lung Cancer: A Meta-analysis of 70 Randomized Controlled Trials. Front Pharmacol, 2021, 12: 582447.
[6] Wang CQ, Huang XR, He M, et al. Intrapleural Administration With Rh-Endostatin and Chemical Irritants in the Control of Malignant Pleural Effusion: A Systematic Review and Meta-Analysis. Front Oncol, 2021, 11: 649999.
[7] He QY, Yu XY, Xiao Z, et al. Comparison of the Efficacy of Danhong Injections at Different Time-points During the Perioperative Period of Acute Myocardial Infarction: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Front Pharmacol, 2021, 12(865): 643446.
[8] Xiao Z, Jiang Y, Wang CQ, et al. Clinical efficacy and safety of aidi injection combination with vinorelbine and cisplatin for advanced non-small-cell lung carcinoma: A systematic review and meta-analysis of 54 randomized controlled trials. Pharmacol Res, 2020, 153: 104637.
[9] Xiao Z, Jiang Y, Chen XF, et al. Intrathoracic infusion therapy with Lentinan and chemical irritants for malignant pleural effusion: a systematic review and meta-analysis of 65 randomized controlled trials. Phytomedicine, 2020, 76: 153260.
[10] Xiao Z, Jiang Y, Chen XF, et al. The Hepatorenal Toxicity and Tumor Response of Chemotherapy With or Without Aidi Injection in Advanced Lung Cancer: A Meta-Analysis of 80 Randomized Controlled Trials. Clin Ther, 2020, 42(3): 515-543 e531.
[11] Zeng FL, Xiao Z, Wang CQ, et al. Clinical efficacy and safety of synthetic thymic peptides with chemotherapy for non-small cell lung cancer in China: A systematic review and meta-analysis of 27 randomized controlled trials following the PRISMA guidelines. Int Immunopharmacol, 2019, 75: 105747.
[12] Xiao Z, Wang CQ, Feng JH, et al. Effectiveness and safety of chemotherapy with cytokine-induced killer cells in non-small cell lung cancer: A systematic review and meta-analysis of 32 randomized controlled trials. Cytotherapy, 2019, 21(2): 125-147.
[13] Xiao Z, Wang C, Zhou M, et al. Clinical efficacy and safety of Aidi injection plus paclitaxel-based chemotherapy for advanced non-small cell lung cancer: A meta-analysis of 31 randomized controlled trials following the PRISMA guidelines. J Ethnopharmacol, 2019, 228: 110-122.
[14] Xiong L, Chen L, Wang C, et al. Clinical Efficacy and Safety of Tanreqing Injection for Pulmonary Infection in Patients with Tuberculosis: A Meta-Analysis. J Altern Complement Med, 2018, 24(11): 1051-1062.
[15] Xiao Z, Wang CQ, Zhou MH, et al. The Antitumor Immunity and Tumor Responses of Chemotherapy with or without DC-CIK for Non-Small-Cell Lung Cancer in China: A Meta-Analysis of 28 Randomized Controlled Trials. J Immunol Res, 2018, 2018: 9081938.
[16] Xiao Z, Wang CQ, Zhou MH, et al. Clinical efficacy and safety of CIK plus radiotherapy for lung cancer: A meta-analysis of 16 randomized controlled trials. Int Immunopharmacol, 2018, 61: 363-375.
[17] Xiao Z, Wang C, Tan Z, et al. Clinical efficacy and safety of sodium cantharidinate plus chemotherapy in non-small-cell lung cancer: A systematic review and meta-analysis of 38 randomized controlled trials. J Clin Pharm Ther, 2019, 44(1): 23-38.
[18] Xiao Z, Wang C, Zhou R, et al. Can Aidi injection improve overall survival in patients with non-small cell lung cancer? A systematic review and meta-analysis of 25 randomized controlled trials. Complement Ther Med, 2018, 37: 50-60.
[19] Xiao Z, Wang C, Li L, et al. Clinical Efficacy and Safety of Aidi Injection Plus Docetaxel-Based Chemotherapy in Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis of 36 Randomized Controlled Trials. Evid Based Complement Alternat Med, 2018, 2018: 7918258.
